secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001601485-25-000072
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025
--------------------------------------------------------------------------------

- Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.
- R&D expense $7.8M, G&A $3.0M; cash and equivalents $18.4M at March 31, 2025.
- DFS event-driven interim analysis of Phase 2 AMPLIFY-7P trial (ELI-002 in PDAC) expected in Q3 2025.
- FDA alignment on key design elements of planned Phase 3 study for ELI-002 in resected mKRAS PDAC.
- Appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/0001601485-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/angn-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer